ASND Stock Analysis: Ascendis Pharma AS | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 16.533m USD | 12M Return: 32.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 132M
Qual. Beats: 0
Rev. Trend: 95.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ascendis Pharma A/S is a Denmark-based biopharmaceutical company (NASDAQ: ASND) that develops TransCon-based therapies targeting unmet medical needs, with operations in Europe, the United States, and other international markets. The company is headquartered in Hellerup, Denmark, and was incorporated in 2006.
Ascendis markets two commercial products: SKYTROFA, a treatment for pediatric growth hormone deficiency, and YORVIPATH, a once-daily subcutaneous injection for adults with chronic hypoparathyroidism. The company is also advancing three independent endocrinology rare disease candidates in clinical development, along with oncology therapeutic candidates in its pipeline.
As a biotechnology firm classified within the Health Care sector, Ascendis operates a research-driven business model in which near-term revenue depends on the commercial uptake of approved products, while long-term growth is tied to the progression of its clinical pipeline and regulatory approvals. Its focus on rare endocrine diseases positions the company to pursue orphan drug pathways, which in major markets typically confer extended exclusivity periods for approved indications.
- SKYTROFA revenue grows on pediatric growth hormone market share gains
- YORVIPATH launch drives adult hypoparathyroidism segment revenue ramp
- TransCon pipeline catalysts in rare disease and oncology ahead
| Net Income: 506.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 22.90 > 1.0 |
| NWC/Revenue: -0.51% < 20% (prev 9.76%; Δ -10.27% < -1%) |
| CFO/TA 0.03 > 3% & CFO 57.6m > Net Income 506.6m |
| Net Debt (423.0m) to EBITDA (12.4m): 34.19 < 3 |
| Current Ratio: 1.00 > 1.5 & < 3 |
| Outstanding Shares: last quarter (64.5m) vs 12m ago 7.50% < -2% |
| Gross Margin: 88.17% > 18% (prev 85.30%; Δ 2.87% > 0.5%) |
| Asset Turnover: 56.57% > 50% (prev 34.74%; Δ 21.84% > 0%) |
| Interest Coverage Ratio: -0.03 > 6 (EBIT TTM -5.03m / Interest Expense TTM 182.5m) |
| A: -0.00 (Total Current Assets 1.12b - Total Current Liabilities 1.13b) / Total Assets 2.01b |
| B: -1.04 (Retained Earnings -2.09b / Total Assets 2.01b) |
| C: -0.00 (EBIT TTM -5.03m / Avg Total Assets 1.53b) |
| D: 0.32 (Book Value of Equity 488.5m / Total Liabilities 1.52b) |
| Altman-Z'' = -3.09 = D |
| DSRI: 1.25 (Receivables 196.8m/66.7m, Revenue 867.5m/368.7m) |
| GMI: 0.97 (GM 85.30% / 88.17%) |
| AQI: 8.31 (AQ_t 0.37 / AQ_t-1 0.04) |
| SGI: 2.35 (Revenue 867.5m / 368.7m) |
| TATA: 0.22 (NI 506.6m - CFO 57.6m) / TA 2.01b) |
| Beneish M = 2.48 (Cap -4..+1) = D |
As of August 03, 2026, the stock is trading at USD 243.91 with a total of 504,632 shares traded. Over the past week, the price has changed by -3.92%, over one month by -11.14%, over three months by +6.65% and over the past year by +32.45%.
Current recommended Stop Loss: 233.80 (which is 4.1% or 1.2 ATR below the current price).
Ascendis Pharma AS has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy ASND.
- StrongBuy: 12
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 307.4 | 26% |
Market Cap EUR = 14.3b (16.5b USD * 0.8678 USD.EUR)
P/E Trailing = 29.2741
P/E Forward = 15.9744
P/S = 19.0957
P/B = 30.0131
Revenue TTM = 867.5m EUR
EBIT TTM = -5.03m EUR
EBITDA TTM = 12.4m EUR
Long Term Debt = 386.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 511.1m EUR (from shortTermDebt, last quarter)
Debt = 996.4m EUR (from shortLongTermDebtTotal, last quarter) + Leases 98.8m
Net Debt = 423.0m EUR (calculated: Debt 996.4m - CCE 573.4m)
Enterprise Value = 14.8b EUR (14.3b + Debt 996.4m - CCE 573.4m)
Interest Coverage Ratio = -0.03 (Ebit TTM -5.03m / Interest Expense TTM 182.5m)
EV/FCF = 350.8x (Enterprise Value 14.8b / FCF TTM 42.1m)
FCF Yield = 0.29% (FCF TTM 42.1m / Enterprise Value 14.8b)
FCF Margin = 4.85% (FCF TTM 42.1m / Revenue TTM 867.5m)
Net Margin = 58.40% (Net Income TTM 506.6m / Revenue TTM 867.5m)
Gross Margin = 88.17% ((Revenue TTM 867.5m - Cost of Revenue TTM 102.6m) / Revenue TTM)
Gross Margin QoQ = 91.37% (prev 88.91%)
Tobins Q-Ratio = 7.37 (Enterprise Value 14.8b / Total Assets 2.01b)
Interest Expense / Debt = 18.32% (Interest Expense 182.5m / Debt 996.4m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -3.97m (EBIT -5.03m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.00 (Total Current Assets 1.12b / Total Current Liabilities 1.13b)
Debt / Equity = 2.04 (Debt 996.4m / totalStockholderEquity, last quarter 488.5m)
Debt / EBITDA = 34.19 (Net Debt 423.0m / EBITDA 12.4m)
Debt / FCF = 10.05 (Net Debt 423.0m / FCF TTM 42.1m)
Total Stockholder Equity = -8.98m (last 4 quarters mean from totalStockholderEquity)
RoA = 33.04% (Net Income 506.6m / Total Assets 2.01b)
RoE = -5.64k% (out of range, set to none) (Net Income TTM 506.6m / Total Stockholder Equity -8.98m)
RoCE = -1.33% (EBIT -5.03m / Capital Employed (Equity -8.98m + L.T.Debt 386.1m))
RoIC = -0.30% (negative operating profit) (NOPAT -3.97m / Invested Capital 1.35b)
WACC = 8.59% (E(14.3b)/V(15.3b) * Re(8.18%) + D(996.4m)/V(15.3b) * Rd(18.32%) * (1-Tc(0.21)))
Discount Rate = 8.18% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.91 | Cagr: 5.98%
[DCF] Terminal Value 74.60% ; FCFF base≈42.1m ; Y1≈42.3m ; Y5≈44.8m
[DCF] Fair Price = 3.76 (EV 669.4m - Net Debt 423.0m = Equity 246.5m / Shares 65.6m; r=8.59% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.29 | # QB: 0
Revenue Correlation: 95.86 | Revenue CAGR: 86.50% | SUE: -0.41 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.77 | Chg30d=+17.05% | Revisions=+0% | Analysts=3
EPS next Quarter (2026-09-30): EPS=1.32 | Chg30d=+10.18% | Revisions=+0% | Analysts=3
EPS current Year (2026-12-31): EPS=11.73 | Chg30d=-2.43% | Revisions=+0% | GrowthEPS=+217.5% | GrowthRev=+86.5%
EPS next Year (2027-12-31): EPS=9.29 | Chg30d=+1.41% | Revisions=+0% | GrowthEPS=-20.8% | GrowthRev=+46.5%
[Analyst] Revisions Ratio: +0% (up=0, down=0)